Good morning :)
Place Order
Add to Watchlist

Akums Drugs and Pharmaceuticals Ltd

AKUMS

Akums Drugs and Pharmaceuticals Ltd

AKUMS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹10,074 cr, stock is ranked 516
High RiskStock is 4.27x as volatile as Nifty
640.104.99% (+30.45)
640.104.99% (+30.45)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹10,074 cr, stock is ranked 516
High RiskStock is 4.27x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹10,074 cr, stock is ranked 516
High RiskStock is 4.27x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
36.2713.98
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.096.400.53%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Akums Drugs and Pharmaceuticals is pharmaceutical contract development and manufacturing company.

Investor Presentation

View older 

Nov 9, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue2,441.652,744.133,694.723,744.894,212.214,121.88
Raw Materialssubtract1,502.951,738.372,432.802,249.872,537.903,732.24
Power & Fuel Costsubtract82.5976.55110.22147.41160.80
Employee Costsubtract438.75424.55507.76590.13646.86
Selling & Administrative Expensessubtract82.57100.99127.52159.99160.81
Operating & Other expensessubtract134.35154.83598.29288.14574.86
Depreciation/Amortizationsubtract66.6869.8494.68112.81125.64134.43
Interest & Other Itemssubtract19.936.7416.6646.2550.6149.74
Taxes & Other Itemssubtract70.1749.5659.3455.44-41.24-72.27
EPS3.0516.41-33.776.63-0.2819.41
DPS0.000.000.000.000.00
Payout ratio0.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025

Annual Report Pending

Investor Presentation

Nov 9PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Akums Drugs and Pharmaceuticals Ltd-2,499.9513.98
Sun Pharmaceutical Industries Ltd44.986.420.75%
Cipla Ltd29.134.480.87%
Torrent Pharmaceuticals Ltd64.7115.630.88%

Price Comparison

Compare AKUMS with any stock or ETF
Compare AKUMS with any stock or ETF
AKUMS
Loading...

Shareholdings

Promoter Holdings Trend

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

No institutional holdings trend are available

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding75.26%5.18%2.35%7.34%9.88%

Feb 2024

Aug 2024

Sep 2024

Shareholding History

FebAugSep0.00%5.32%7.34%

Mutual Funds Holding Trend

No mutual funds holding trends are available

Top 5 Mutual Funds holding Akums Drugs and Pharmaceuticals Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Franklin India Smaller Companies Fund - Growth - Direct Plan

Growth
1.4457%1.04%0.93%63/103 (+24)
SBI Healthcare Opportunities Fund - Growth - Direct Plan

Growth
0.7521%2.22%0.04%22/33 (-3)
Franklin India Opportunities Fund - Growth - Direct Plan

Growth
0.6472%1.16%1.03%57/74 (+5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

AKUMS has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Spotlight
Akums Drugs hits life high on inking pact with Caregen

Under the agreement, Akums was granted exclusive rights to sell a selection of Caregen's products in India for the duration of the partnership. The company would also be responsible for the packaging, marketing, and selling of Caregen's bulk products under either Caregen's trademark, Akums' trademark, or Akums' clients' trademarks. Caregen is a global leader in peptide research and development and a global biotechnology company based in South Korea that has commercialized the unlimited expandability of its patented peptides as many innovative products. Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The pharma company consolidated net profit spiked 104.96% to Rs 65.20 crore despite of 12.54% declined in revenue from operations to Rs 1,033.1 crore in Q2 FY25 over Q2 FY245.Powered by Capital Market - Live

4 days agoCapital Market - Live
Earnings
Akums Drugs & Pharmaceuticals consolidated net profit rises 105.00% in the September 2024 quarter

Net profit of Akums Drugs & Pharmaceuticals rose 105.00% to Rs 65.21 crore in the quarter ended September 2024 as against Rs 31.81 crore during the previous quarter ended September 2023. Sales declined 12.54% to Rs 1033.09 crore in the quarter ended September 2024 as against Rs 1181.25 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1033.091181.25 -13 OPM %11.7312.85 - PBDT122.75144.95 -15 PBT87.89114.53 -23 NP65.2131.81 105 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Akums Drugs & Pharmaceuticals to conduct board meeting

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Akums Drugs signs license & distribution agreement with Triple Hair Inc.

Akums Drugs & Pharmaceuticals has entered into a License & Distribution Agreement with Triple Hair Inc, a company duly incorporated under the laws of New Brunswick, Canada, having its registered office at 5085 Principale-Est Av, Dieppe, New Brunswick, Canada. As per the terms of the agreement, Company has been granted the exclusive rights to further develop and market the products recently innovated by Triple Hair Inc, in the Territory of India. The Company will undertake this development and commercialization after obtaining the necessary regulatory approvals or requisite licenses in India. The agreement grants the Company exclusive right to use Triple Hair's intellectual property rights (Patent) solely to carry out the studies and perform the services as stipulated in the agreement. Further, Company will manage the commercial strategy to promote and offer Triple Hair's patented products to its own marketing partners and clients within the Indian market exclusively. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Akums Drugs and Pharma reports turnaround Q1 numbers

Revenue from operations was at Rs 1,019 crore in the quarter ended 30 June 2024, up 5.06% as against with Rs 969.89 crore posted in corresponding quarter last year. Profit before tax stood at Rs 87.47 crore in Q1 FY25 as compared pre tax loss of Rs 158.79 crore reported in Q1 FY24. The firm reported quarterly EBITDA of Rs 130.70 crore in Q1 FY25, registering a growth of 21.01% year on year. EBITDA margin improved to 12.7% in Q1 FY25 as compared to 11% recorded in the corresponding quarter previous year. The company's revenue from CMDO business was at Rs 782 crore in Q1 FY25, up 5.60% as against with Rs 740.50 crore posted in Q1 FY24. This was driven by strong growth in sales volume of 13.9%. Branded and generic formulations segment revenue stood at Rs 167.40 crore during the quarter, marking a de-growth of 12.49% year on year basis. The API segment revenue jumped 82.46% to Rs 69.70 crore in Q1 FY25 as against with Rs 38.20 crore posted in the corresponding quarter previous year. As on 30 June 2024, debt to equity improved to 0.25 times with Net debt at Rs 212.80 crore. Commenting on the financial performance, Sanjeev Jain, MD, Akums Drugs & Pharmaceuticals, stated, 'Our Q1 results show our ongoing efforts to optimize our operations and capitalise on our strengths in the CDMO segment. We are committed to driving sustainable growth across all our business segments and delivering value to our stakeholders.' Meanwhile, the company's board announced the new Injectable facility housed in Akums Healthcare started commercial production on 22 August 2024, with a capacity of 362 million units annually. Akums already has a significant presence in injectable CDMO space and this new facility is expected to consolidate its leadership position in Indian CDMO market. Further, the board of directors, approved a plan to set up two production facilities in Jammu at an overall investment of Rs 265 crore. These will be multi-dosage facilities across pharmaceutical and nutraceutical products. Speaking on the company's plans, Sandeep Jain, MD, Akums Drugs & Pharmaceuticals, said, 'The launch of our injectable facility and the Jammu expansion are key steps in our strategy to enhance our production capabilities. These developments, coupled with our ongoing efforts in R&D and innovation, are aligned with our endeavour to respond effectively to the evolving demands of our clients and the healthcare industry.' Lastly, the company's board appointment Amrut Medhekar as a Chief Executive Officer, CDMO business with effect from 24 August, 2024. Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The script slipped 2.97% to currently trade at Rs 913.05 on the BSE.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Akums Drugs & Pharmaceuticals reports consolidated net profit of Rs 60.17 crore in the June 2024 quarter

Net profit of Akums Drugs & Pharmaceuticals reported to Rs 60.17 crore in the quarter ended June 2024 as against net loss of Rs 188.23 crore during the previous quarter ended June 2023. Sales rose 5.07% to Rs 1019.11 crore in the quarter ended June 2024 as against Rs 969.89 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1019.11969.89 5 OPM %12.56-12.92 - PBDT121.54-129.33 LP PBT87.48-159.04 LP NP60.17-188.23 LP Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Akums Drugs & Pharmaceuticals to discuss results

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live